Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of FX-345 in adults with acquired sensorineural hearing loss
NCT05664100Phase 1Terminated
- Sponsor
- Frequency Therapeutics
- Start
- Dec 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of FX-345 in sensorineural hearing loss (SNHL) (4 cohorts), sponsored by Frequency Therapeutics. Primary endpoints: Number of Participants With Treatment-emergent Adverse Event(s), Maximum Observed Plasma Concentration at 24 hours and 6 more. Started Dec 2022; status: terminated.
02
Drugs
FX-345
03
Conditions
sensorineural hearing loss (SNHL)
Beyond the preview
Go deeper on NCT05664100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05664100.